It is the first peptide that simultaneously activates three key receptors: GLP-1, GIP, and glucagon
Kaiser California removed GLP-1 weight loss drugs from base coverage for members with BMI under 40 effective 1/1/2025
Marys Hospital, The Catholic University of Korea) to evaluate the safety, tolerability, and pharmacokinetics of subcutaneous PG-102 in healthy individuals with overweight (body mass index 2530 kg/m), with exploratory pharmacodynamic and biomarker assessments
Semaglutide produces substantial weight loss at $199 monthly in compounded form
As a registered dietitian, I was curious to better understand what's actually in the product, what the research does and doesn't show and who Pendulum's products may be a good fit for
Behavioral modification programs with professional support